Lars‐Olof Mügge - Concepedia

Author

Lars‐Olof Mügge

Also Known As

L Mügge, L O Mügge, L-O Mügge, L. Mugge, L. Mügge, L.-O. Mügge, L.O. Mügge, Lars-Olof Mugge, Lars-Olof Mügge, Lars-Olof Mügge

Publications

468

Citations

H-Index

Concepts

All Affiliations

Jena University Hospital Universitätsklinikum Würzburg Friedrich Schiller University Jena Universitätsmedizin Greifswald University of Rostock

About

Lars‐Olof Mügge is an author at Jena University Hospital specializing in medicine, hematology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	203
2	Health Sciences	4	4	105
3	Blood Transplantation	1	1	29
4	Cell Biology	1	1	17
5	Cellular Therapies	1	1	17

Lars‐Olof Mügge

Publications

326

Citations

H-Index

Page 1

	Year	Citations
Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia Sebastian Scholl, Claudia med. Theuer, Veit Scheble, European Journal Of Haematology	2007	69
The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey Annamaria Brioli, Maximilian Klaus, Herbert G. Sayer, Annals of Hematology Hematological MalignancyMedicineMalignant Blood DisorderImmunologyClinical Epidemiology	2019	52
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, The Lancet Haematology Hematological MalignancyOncologyTransplantationHematologyClinical Trials	2022	44
Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial). Hermann Einsele, Peter Liebisch, Christian Langer, Blood	2009	43
Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia Sebastian Scholl, Lars‐Olof Mügge, Olfert Landt, Leukemia Research Sensitive DetectionChromatinHematological MalignancyMedicineMixed-phenotype Acute Leukemia	2007	33
Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors Christoph Kasper, Herbert G. Sayer, Lars‐Olof Mügge, Bone Marrow Transplantation Unrelated DonorsGraft-versus-host DiseaseTransplantationMarrow TransplantationMycophenolate Mofetil	2004	29
Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT Sebastian Scholl, Lars‐Olof Mügge, Miriam Charbel Issa, Bone Marrow Transplantation Cell TherapyViral PersistenceImmunologyDose-reduced RegimenAntiviral Response	2004	17
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077) Juliane Beck, Andreas Schwarzer, Dietrich Gläser, Journal of Cancer Research and Clinical Oncology Hematological MalignancyOncologyHematologyMyeloid NeoplasiaPathology	2017	14
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN) Annamaria Brioli, Kirsi Manz, Markus Pfirrmann, Journal of Cancer Research and Clinical Oncology Hematological MalignancyOncologyAgingGeriatricsLongevity	2019	14
Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort Annamaria Brioli, Theresa Maria Nägler, Olaposi Yomade, Oncology Research and Treatment	2022	11

Page 1